Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Treatment Patterns Among Newly Diagnosed Multiple Myeloma Patients in the United States Veteran Population (2010-2015)

Kejal Parikh, Shivani Pandya, MS, Safiya Abouzaid, Onur Baser, MS, PhD, Lin Xie, MA, MS, Manali I. Patel, MD MPH, MS

Blood (2016) 128 (22): 5952.

https://doi.org/10.1182/blood.V128.22.5952.5952

Published: 2016

Journal Articles

Real World Treatment Outcomes and Cost Among Newly-Diagnosed Multiple Myeloma Patients Treated with Bortezomib and Dexamethasone in Combination with Cyclophosphamide or Lenalidomide

Lin Xie, MA, MS, Kejal Parikh, Safiya Abouzaid, Shivani Pandya, MS, Onur Baser, MS, PhD, Manali I. Patel, MD MPH, MS

Blood (2016) 128 (22): 5924.

https://doi.org/10.1182/blood.V128.22.5924.5924

Published: 2016

Journal Articles

Are Racial and Ethnic Disparities in Mortality from Acute Leukemia Due to Socioeconomic Status Factors? Data from the Surveillance Epidemiology and End Results Database Linked to the National Longitudinal Mortality Study

Manali I. Patel, MD MPH, MS, Norman Johnson, PhD, Sean Altekruse, DVM, MPH, PhD, Kim Rhoads, MDMPH

Blood (2015) 126 (23): 2101.

https://doi.org/10.1182/blood.V126.23.2101.2101

Published: 2015

Journal Articles

Are There Disparities in Transplant-Related Morbidity and Mortality after Hematopoietic Stem Cell Transplant: An Institution-Based Analysis of Autologous and Allogeneic Transplant Recipients

Manali I. Patel, MD MPH, Clayton Schupp, Scarlett Lin Gomez, PhD, Robert Lowsky, MD, Holbrook E Kohrt, MD

Blood (2014) 124 (21): 1283.

https://doi.org/10.1182/blood.V124.21.1283.1283

Published: 2014

Journal Articles

Are Racial and Ethnic Disparities In Acute Myeloid Leukemia Due To Differences In Treatment?

Manali I. Patel, MD, MPH, Yifei Ma, MS, Beverly S. Mitchell, Kim Rhoads, MS MD MPH

Blood (2013) 122 (21): 726.

https://doi.org/10.1182/blood.V122.21.726.726

Published: 2013

Journal Articles

Are Disparities in Acute Myelogenous Leukemia Due to Poor Prognostic Factors At Diagnosis? A National Study

Manali I. Patel, MD, MPH, Yifei Ma, MS, Beverly S. Mitchell, Kim Rhoads, MS MD MPH

Blood (2012) 120 (21): 2061.

https://doi.org/10.1182/blood.V120.21.2061.2061

Published: 2012

NARROW

Treatment Patterns Among Newly Diagnosed Multiple Myeloma Patients in the United States Veteran Population (2010-2015)

Real World Treatment Outcomes and Cost Among Newly-Diagnosed Multiple Myeloma Patients Treated with Bortezomib and Dexamethasone in Combination with Cyclophosphamide or Lenalidomide

Are Racial and Ethnic Disparities in Mortality from Acute Leukemia Due to Socioeconomic Status Factors? Data from the Surveillance Epidemiology and End Results Database Linked to the National Longitudinal Mortality Study

Are There Disparities in Transplant-Related Morbidity and Mortality after Hematopoietic Stem Cell Transplant: An Institution-Based Analysis of Autologous and Allogeneic Transplant Recipients

Are Racial and Ethnic Disparities In Acute Myeloid Leukemia Due To Differences In Treatment?

Are Disparities in Acute Myelogenous Leukemia Due to Poor Prognostic Factors At Diagnosis? A National Study

Email alerts

ASH Publications

American Society of Hematology

Treatment Patterns Among Newly Diagnosed Multiple Myeloma Patients in the United States Veteran Population (2010-2015)

Real World Treatment Outcomes and Cost Among Newly-Diagnosed Multiple Myeloma Patients Treated with Bortezomib and Dexamethasone in Combination with Cyclophosphamide or Lenalidomide

Are Racial and Ethnic Disparities in Mortality from Acute Leukemia Due to Socioeconomic Status Factors? Data from the Surveillance Epidemiology and End Results Database Linked to the National Longitudinal Mortality Study

Are There Disparities in Transplant-Related Morbidity and Mortality after Hematopoietic Stem Cell Transplant: An Institution-Based Analysis of Autologous and Allogeneic Transplant Recipients

Are Racial and Ethnic Disparities In Acute Myeloid Leukemia Due To Differences In Treatment?

Are Disparities in Acute Myelogenous Leukemia Due to Poor Prognostic Factors At Diagnosis? A National Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only